Download PDF
Dtsch Med Wochenschr 2020; 145(01): 19-28
DOI: 10.1055/a-0793-4513
Dossier
© Georg Thieme Verlag KG Stuttgart · New York

Lyme-Borreliose: Kutane und neurologische Manifestationen, Falldefinitionen und Therapie

Lyme Borreliosis: Cutaneous and Neurologic Manifestations, Case Definitions and Therapy
Cora Scheerer
,
Rick Dersch
,
Hans-Iko Huppertz
,
Heidelore Hofmann
Further Information

Publication History

Publication Date:
08 January 2020 (online)

Also available at
    Permissions and Reprints

Abstract

Lyme borreliosis is the most common zoonosis in Germany with an incidence of up to 138/100 000. More than 90 % of all cases show dermatological manifestations. Early manifestations are erythema migrans, multiple erythemata migrantia, and (less frequently) borrelial lymphocytoma. A typical late manifestation is acrodermatitis chronica atrophicans. Lyme neuroborreliosis is much less common with an incidence of about 0.8/100 000 inhabitants in Germany. Bannwarth’s syndrome (painful radiculoneuritis) is the most common manifestation of Lyme neuroborreliosis in adults followed by meningitis. International case definitions exist regarding the likelihood of Lyme neuroborreliosis on the basis of diagnostic test results. A CSF analysis should be performed in patients with suspected Lyme neuroborreliosis. The first line treatment for dermatological manifestations of Lyme borreliosis is doxycycline, in children and pregnant women amoxicillin. Doxycycline and beta-lactam antibiotics show similar efficacy regarding neurological symptoms and adverse effects for treatment of neurological manifestations. Treatment duration for early manifestations is 10 to 14 days, in Lyme neuroborreliosis it should not exceed 21 days. All manifestations, also Lyme neuroborreliosis, usually show a favourable prognosis after antibiotic treatment. Antibiotic treatment does not show any efficacy in patients with unspecific symptoms and concurrent positive anti-borrelial serology.

Hautsymptome nach Zeckenbiss sind als „Wanderröte“ allgemein bekannt. Borrelien verursachen aber auch andere Manifestationen, deren Falldefinitionen der Praktiker kennen sollte. Ebenso steht bei unspezifischen Beschwerden zuweilen die Frage nach einer Neuroborreliose im Raum, die nicht voreilig mit der Gabe von Antibiotika beantwortet werden darf. Diagnostische Parameter und Therapieoptionen stellt dieser Beitrag kompakt vor.

Schlüsselwörter

Lyme-Borreliose - Erythema migrans - Acrodermatitis chronica atrophicans - Neuroborreliose - Posttreatment-Lyme-Disease-Syndrom

Key words

Lyme borreliosis - erythema migrans - acrodermatitis chronica atrophicans - neuroborreliosis - posttreatment Lyme disease syndrome
 

  • Literatur

  • 1 Enkelmann J, Böhmer M, Fingerle V. et al. Incidence of notified Lyme borreliosis in Germany, 2013–2017. Sci Rep 2018; 8: 14976
    CrossrefPubMedGoogle Scholar
  • 2 Wilhelmsson P, Fryland L, Lindblom P. et al. A prospective study on the incidence of Borrelia burgdorferi sensu lato infection after a tick bite in Sweden and on the Aland Islands, Finland (2008–2009). Ticks Tick Borne Dis 2016; 7: 71-79
    CrossrefPubMedGoogle Scholar
  • 3 Berglund J, Eitrem R, Ornstein K. et al. An epidemiologic study of Lyme disease in southern Sweden. N Engl J Med 1995; 333: 1319-1327
    CrossrefPubMedGoogle Scholar
  • 4 Glatz M, Resinger A, Semmelweis K. et al. Clinical spectrum of skin manifestations of Lyme borreliosis in 204 children in Austria. Acta Derm Venereol 2015; 95: 565-571
    PubMedGoogle Scholar
  • 5 Huppertz HI, Böhme M, Standaert SM. et al. Incidence of Lyme borreliosis in the Wurzburg region of Germany. Eur J Clin Microbiol Infect Dis 1999; 18: 697-703
    CrossrefPubMedGoogle Scholar
  • 6 Strle F, Lusa L, Ružić-Sabljić E. et al. Clinical characteristics associated with Borrelia burgdorferi sensu lato skin culture results in patients with erythema migrans. PLoS One 2013; 8: e82132
    CrossrefPubMedGoogle Scholar
  • 7 Stanek G, Fingerle V, Hunfeld KP. et al. Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect 2011; 17: 69-79
    CrossrefPubMedGoogle Scholar
  • 8 Cardenas-de la Garza JA, De la Cruz-Valadez E, Ocampo-Candiani J. et al. Clinical spectrum of Lyme disease. Eur J Clin Microbiol Infect Dis 2019; 38: 201-208
    CrossrefPubMedGoogle Scholar
  • 9 Arnez M, Pleterski-Rigler D, Luznik-Bufon T. et al. Children with multiple erythema migrans: are there any pre-treatment symptoms and/or signs suggestive for central nervous system involvement?. Wien Klin Wochenschr 2002; 114: 524-529
    PubMedGoogle Scholar
  • 10 Moniuszko-Malinowska A, Czupryna P, Dunaj J. et al. Acrodermatitis chronica atrophicans: various faces of the late form of Lyme borreliosis. Postepy Dermatol Alergol 2018; 35: 490-494
    PubMedGoogle Scholar
  • 11 Maraspin V, Mrvič T, Ružić-Sabljić E. et al. Acrodermatitis chronica atrophicans in children: Report on two cases and review of the literature. Ticks Tick Borne Dis 2019; 10: 180-185
    CrossrefPubMedGoogle Scholar
  • 12 Kindstrand E, Nilsson BY, Hovmark A. et al. Peripheral neuropathy in acrodermatitis chronica atrophicans – a late Borrelia manifestation. Acta Neurol Scand 1997; 95: 338-345
    CrossrefPubMedGoogle Scholar
  • 13 Asbrink E. Acrodermatitis chronica atrophicans. Clin Dermatol 1993; 11: 369-375
    PubMedGoogle Scholar
  • 14 Kjaer M, Jensen B, Clemmensen A. Acrodermatitis chronica atrophicans-probably an overlooked differential diagnosis for arthritis. Rheumatology (Oxford) 2016: pii: kew392 . [Epub ahead of print]
    PubMedGoogle Scholar
  • 15 Hofmann H, Fingerle V, Hunfeld KP. et al. Cutaneous Lyme borreliosis: Guideline of the German Dermatology Society. Ger Med Sci 2017; 15: Doc14
    PubMedGoogle Scholar
  • 16 Stupica D, Maraspin V, Bogovic P. et al. Comparison of Clinical Course and Treatment Outcome for Patients With Early Disseminated or Early Localized Lyme Borreliosis. JAMA Dermatol 2018; 154: 1050-1056
    CrossrefPubMedGoogle Scholar
  • 17 Dersch R, Freitag MH, Schmidt S. et al. Efficacy and safety of pharmacological treatments for acute Lyme neuroborreliosis – a systematic review. Eur J Neurol 2015; 22: 1249-1259
    CrossrefPubMedGoogle Scholar
  • 18 Torbahn G, Hofmann H, Rücker G. et al. Efficacy and Safety of Antibiotic Therapy in Early Cutaneous Lyme Borreliosis: A Network Meta-analysis. JAMA Dermatol 2018; 154: 1292-1303
    CrossrefPubMedGoogle Scholar
  • 19 Wilking H, Stark K. Trends in surveillance data of human Lyme borreliosis from six federal states in eastern Germany, 2009–2012. Ticks Tick-Borne Dis 2014; 5: 219-224
    CrossrefPubMedGoogle Scholar
  • 20 Hofhuis A, Harms M, Bennema S. et al. Physician reported incidence of early and late Lyme borreliosis. Parasit Vectors 2015; 8: 161
    CrossrefPubMedGoogle Scholar
  • 21 Eliassen KE, Berild D, Reiso H. et al. Incidence and antibiotic treatment of erythema migrans in Norway 2005–2009. Ticks Tick-Borne Dis 2017; 8: 1-8
    CrossrefPubMedGoogle Scholar
  • 22 Pfister HW, Einhäupl KM, Wilske B. et al. Bannwarth’s syndrome and the enlarged neurological spectrum of arthropod-borne borreliosis. Zentralblatt Bakteriol Mikrobiol Hyg Ser Med Microbiol Infect Dis Virol Parasitol 1987; 263: 343-347
    PubMedGoogle Scholar
  • 23 Kaiser R. Clinical courses of acute and chronic neuroborreliosis following treatment with ceftriaxone. Nervenarzt 2004; 75: 553-557
    PubMedGoogle Scholar
  • 24 Back T, Grünig S, Winter Y. et al. Neuroborreliosis-associated cerebral vasculitis: long-term outcome and health-related quality of life. J Neurol 2013; 260: 1569-1575
    CrossrefPubMedGoogle Scholar
  • 25 Mygland A, Skarpaas T, Ljøstad U. Chronic polyneuropathy and Lyme disease. Eur J Neurol 2006; 13: 1213-1215
    CrossrefPubMedGoogle Scholar
  • 26 Wilking H, Fingerle V, Klier C. et al. Antibodies against Borrelia burgdorferi sensu lato among Adults, Germany, 2008–2011. Emerg Infect Dis 2015; 21: 107-110
    CrossrefPubMedGoogle Scholar
  • 27 Rauer S, Kastenbauer S. et al. Neuroborreliose, S3-Leitlinie 2018. In: Deutsche Gesellschaft für Neurologie, Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie. Im Internet: www.dgn.org/leitlinien . Stand: 3.10.2019
    PubMedGoogle Scholar
  • 28 Rupprecht TA, Manz KM, Fingerle V. et al. Diagnostic value of cerebrospinal fluid CXCL13 for acute Lyme neuroborreliosis. A systematic review and meta-analysis. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 2018; 24: 1234-1240
    PubMedGoogle Scholar
  • 29 Rupprecht TA, Lechner C, Tumani H. et al. CXCL13: a biomarker for acute Lyme neuroborreliosis: investigation of the predictive value in the clinical routine. Nervenarzt 2014; 85: 459-464
    CrossrefPubMedGoogle Scholar
  • 30 Dersch R, Freitag MH, Schmidt S. et al. Efficacy and safety of pharmacological treatments for acute Lyme neuroborreliosis – a systematic review. Eur J Neurol 2015; 22: 1249-1259
    CrossrefPubMedGoogle Scholar
  • 31 Dersch R, Hottenrott T, Schmidt S. et al. Efficacy and safety of pharmacological treatments for Lyme neuroborreliosis in children: a systematic review. BMC Neurol 2016; 16: 189
    CrossrefPubMedGoogle Scholar
  • 32 Oksi J, Nikoskelainen J, Hiekkanen H. et al. Duration of antibiotic treatment in disseminated Lyme borreliosis: a double-blind, randomized, placebo-controlled, multicenter clinical study. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol 2007; 26: 571-581
    CrossrefPubMedGoogle Scholar
  • 33 Solheim AM, Ljøstad U, Mygland Å. Six versus two weeks treatment with doxycycline in Lyme neuroborreliosis: the protocol of a multicentre, non-inferiority, double-blinded and randomised controlled trial. BMJ Open 2019; 9: e027083
    CrossrefPubMedGoogle Scholar
  • 34 Dersch R, Sarnes AA, Maul M. et al. Quality of life, fatigue, depression and cognitive impairment in Lyme neuroborreliosis. J Neurol 2015; 262: 2572-2577
    CrossrefPubMedGoogle Scholar
  • 35 Kalish RA, Kaplan RF, Taylor E. et al. Evaluation of study patients with Lyme disease, 10–20-year follow-up. J Infect Dis 2001; 183: 453-460
    CrossrefPubMedGoogle Scholar
  • 36 Klempner MS, Hu LT, Evans J. et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001; 345: 85-92
    CrossrefPubMedGoogle Scholar
  • 37 Lantos PM, Auwaerter PG, Wormser GP. A systematic review of Borrelia burgdorferi morphologic variants does not support a role in chronic Lyme disease. Clin Infect Dis Off Publ Infect Dis Soc Am 2014; 58: 663-671
    CrossrefPubMedGoogle Scholar
  • 38 Fallon BA, Keilp JG, Corbera KM. et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 2008; 70: 992-1003
    CrossrefPubMedGoogle Scholar
  • 39 Krupp LB, Hyman LG, Grimson R. et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 2003; 60: 1923-1930
    CrossrefPubMedGoogle Scholar
  • 40 Sjöwall J, Ledel A, Ernerudh J. et al. Doxycycline-mediated effects on persistent symptoms and systemic cytokine responses post-neuroborreliosis: a randomized, prospective, cross-over study. BMC Infect Dis 2012; 12: 186
    CrossrefPubMedGoogle Scholar
  • 41 Berende A, ter Hofstede HJM, Vos FJ. et al. Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease. N Engl J Med 2016; 374: 1209-1220
    CrossrefPubMedGoogle Scholar
  • 42 Berende A, Ter Hofstede HJM, Vos FJ. et al. Effect of prolonged antibiotic treatment on cognition in patients with Lyme borreliosis. Neurology 2019; 92: e1447-e1455
    CrossrefPubMedGoogle Scholar